USA flag logo/image

An Official Website of the United States Government

DEVELOPMENT OF A STABLE ULTRASOUND CONTRAST AGENT

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
7339
Program Year/Program:
1987 / SBIR
Agency Tracking Number:
7339
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Molecular Biosystems Inc
10030 Barnes Canyon Rd San Diego, CA 92121
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1987
Title: DEVELOPMENT OF A STABLE ULTRASOUND CONTRAST AGENT
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

UNTIL RECENTLY, CARDIAC ULTRASOUND HAS OFFERED NO METHOD OF EVALUATING MYOCARDIAL PERFUSION OTHER THAN ASSESSMENT OF THEEND RESULTS OF ISCHEMIA, SUCH AS WALL MOTION ABNORMALITIES. RECENT ATTEMPTS AT DEVELOPING AN EFFECTIVE CONTRAST AGENT TO MEASURE MYOCARDIAL PERFUSION HAVE RESULTED IN THE DEVELOPMENT OF MICROBUBBLES, UNSTABLE PREPARATIONS OF AIR TRAPPED IN FLUID WHICH SERVE AS HIGHLY ECHOGENIC MEDIA. CLINICAL UTILITY OF CONTRAST ULTRASONOGRAPHY FOR MEASURING BLOOD FLOW IS CRITICALLY DEPENDENT ON THE DEVELOPMENT OF STABLE MICROBUBBLES THAT ARE SMALL ENOUGH FOR UNHINDERED CAPILLARY PASSAGE FOR INTRAVENOUS INJECTION. THE PHASE I GOAL IS TO DEVELOP REPRODUCIBLE, STABLE, SMALL, AIR-TRAPPED SPHERES TO SERVE AS A PERFUSION CONTRAST AGENT. THE AGENT WILL OPTIMALLY CONSIST OF 2.0-MICRON-DIAMETER, AIR-TRAPPED SPHERES, WHICH WILL BE TESTED FOR SHELF-LIFE AND ECHOGENIC PROPERTIES. WHEN STABLE PREPARATIONS ARE MADE, TESTS WILL BE PERFORMED BOTH IN VITRO AND IN VIVO TO DEMONSTRATE CONTRAST EFFICACY. THE RESULTS OF PHASE I WILL SERVE AS A BASIS DURING PHASE II TO PERFORM FULL TOXICITY TESTING IN RODENTS AND DOGS. AFTER SUCCESSFUL COMPLETION OF TOXICITY TESTING, AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION WILL BE FILED AND CLINICAL EVALUATION PERFORMED TO OBTAIN FOOD AND DRUG ADMINISTRATION APPROVAL. SUCCESSFUL DEVELOPMENT OF A STABLE ULTRASOUND CONTRAST AGENT WILL HAVE WIDE APPLICABILITY, NOT ONLY IN MONITORING CARDIAC PERFUSION BUT ALSO IN THE ASSESSMENT OF TISSUE PERFUSION IN OTHER ANATOMIC SITES.

Principal Investigator:

Kenneth j widd md
6194520681

Business Contact:

Small Business Information at Submission:

Molecular Biosystems Inc
11180-a Roselle Street San Diego, CA 92121

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No